Interius BioTherapeutics is a preclinical-stage biotechnology company focused on developing novel therapies for the treatment of cancer and other diseases. The company's lead product candidate, INT-001, is a small molecule inhibitor of the protein CDK7, which plays a key role in the regulation of gene expression. By inhibiting CDK7, INT-001 has the potential to disrupt the growth and survival of cancer cells, and may also have applications in other diseases such as inflammation and fibrosis. Interius BioTherapeutics was founded in 2019 and is headquartered in Cambridge, Massachusetts.